FDA & EMA approvals for rare genetic diseases are fast and require clinical studies with small number of patients Ramat Gan, Israel, March ...
Results from Phase 2 RAINFOLTM-01 trial (B1 cohort) showed that with a median on-study follow-up of 48 weeks, Rina-S 120 mg/m2 led to a confirmed objective response rate (ORR) of 55.6% and median ...
Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results